Zacks: Brokerages Anticipate Cardiovascular Systems Inc (CSII) Will Post Earnings of $0.04 Per Share

Brokerages expect Cardiovascular Systems Inc (NASDAQ:CSII) to post earnings of $0.04 per share for the current quarter, Zacks reports. Four analysts have provided estimates for Cardiovascular Systems’ earnings. The highest EPS estimate is $0.05 and the lowest is $0.02. Cardiovascular Systems reported earnings per share of $0.11 in the same quarter last year, which indicates a negative year over year growth rate of 63.6%. The firm is scheduled to issue its next quarterly earnings results on Monday, July 29th.

On average, analysts expect that Cardiovascular Systems will report full year earnings of ($0.01) per share for the current financial year, with EPS estimates ranging from ($0.04) to $0.00. For the next fiscal year, analysts forecast that the business will post earnings of $0.08 per share, with EPS estimates ranging from $0.01 to $0.12. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Cardiovascular Systems.

Cardiovascular Systems (NASDAQ:CSII) last announced its earnings results on Wednesday, May 1st. The medical device company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. Cardiovascular Systems had a net margin of 0.84% and a return on equity of 1.47%. The business had revenue of $63.31 million for the quarter, compared to analyst estimates of $62.80 million.

A number of research firms recently weighed in on CSII. BidaskClub upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a research report on Wednesday, May 8th. Needham & Company LLC reiterated a “hold” rating on shares of Cardiovascular Systems in a research report on Thursday, May 2nd. Zacks Investment Research upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Thursday, April 18th. Bank of America lowered shares of Cardiovascular Systems from a “buy” rating to an “underperform” rating and set a $42.00 price objective on the stock. in a research report on Thursday, April 11th. They noted that the move was a valuation call. Finally, ValuEngine upgraded shares of Cardiovascular Systems from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $44.00.

NASDAQ:CSII opened at $39.90 on Friday. Cardiovascular Systems has a 1-year low of $24.84 and a 1-year high of $42.64. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.78 and a current ratio of 4.25. The firm has a market capitalization of $1.39 billion, a P/E ratio of 798.00 and a beta of 2.08.

Large investors have recently bought and sold shares of the stock. Prudential Financial Inc. boosted its position in shares of Cardiovascular Systems by 1.5% during the 4th quarter. Prudential Financial Inc. now owns 32,495 shares of the medical device company’s stock worth $926,000 after purchasing an additional 471 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Cardiovascular Systems by 0.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 139,721 shares of the medical device company’s stock worth $3,980,000 after purchasing an additional 523 shares in the last quarter. American International Group Inc. boosted its position in shares of Cardiovascular Systems by 3.6% during the 4th quarter. American International Group Inc. now owns 22,304 shares of the medical device company’s stock worth $635,000 after purchasing an additional 765 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Cardiovascular Systems by 21.7% during the 4th quarter. Legal & General Group Plc now owns 6,065 shares of the medical device company’s stock worth $173,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Quantamental Technologies LLC purchased a new stake in shares of Cardiovascular Systems during the 4th quarter worth $37,000. Hedge funds and other institutional investors own 92.06% of the company’s stock.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Featured Article: Growth and Income Funds

Get a free copy of the Zacks research report on Cardiovascular Systems (CSII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.